We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · July 23, 2021

Risk of Malignancy With Vedolizumab vs TNF-α Antagonists in Patients With IBD

Digestive Diseases and Sciences

 

Additional Info

Disclosure statements are available on the authors' profiles:

Digestive Diseases and Sciences
Risk of Malignancy With Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases
Dig. Dis. Sci. 2021 Jun 03;[EPub Ahead of Print], S Singh, HC Heien, L Sangaralingham, ND Shah, WJ Sandborn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.